WO2007116980A1 - 血糖値上昇抑制剤 - Google Patents
血糖値上昇抑制剤 Download PDFInfo
- Publication number
- WO2007116980A1 WO2007116980A1 PCT/JP2007/057790 JP2007057790W WO2007116980A1 WO 2007116980 A1 WO2007116980 A1 WO 2007116980A1 JP 2007057790 W JP2007057790 W JP 2007057790W WO 2007116980 A1 WO2007116980 A1 WO 2007116980A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fucoxanthin
- blood glucose
- glucose level
- increase
- added
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to a blood glucose level increase inhibitor comprising fucoxanthin as an active ingredient.
- Non-Patent Documents 1 to 4 Various chemical substances derived from natural products that suppress an increase in blood glucose level have been reported, such as components of traditional Chinese medicines and components of higher plants. Furthermore, many substances that suppress the increase in blood glucose level are also found in the substances contained in seaweed. For example, it has been reported that polysaccharides such as fucoidan and alginic acid have physiological functions such as an inhibitory effect on blood glucose level elevation and blood lipid elevation suppression (Patent Document 16).
- substances that are supposed to be inhibitors of blood glucose level increase are fucoidan, fucoidan degradation product, fucoidan salt, fucoidan degradation product salt, sodium alginate, seaweed containing all of the above substances in a broad sense.
- seaweed contains these water-soluble components extracted with hot water, acid, alkaline aqueous solution, and the like, and fat-soluble components extracted with an organic solvent such as ethanol.
- water-soluble components the proportion of seaweed in the seaweed is overwhelmingly large, so there is a history of its extensive application.
- the bioactivity of fat-soluble components was hardly investigated until recently, when the proportion in seaweed was as low as about 1%.
- Fucoxanthin one of the fat-soluble substances contained in seaweed, is a type of carotenoid and is the most abundant carotenoid among 13 naturally occurring carotenoids. one of.
- the amount of fucoxanthin contained in seaweed is about 0.1% by weight with respect to dry seaweed, its physiological function has hardly been investigated so far.
- seaweed powder or seaweed extract when suppressing the increase in blood glucose level using seaweed powder or seaweed extract, it is necessary to identify which substances are effective in suppressing the increase in blood glucose level, and therefore take a large amount of seaweed powder or seaweed extract. There was a problem of having to. Furthermore, when seaweed powder or seaweed extract is used, there is a problem that the odor and flavor peculiar to seafood are shifted to foods and beverages to be added. For Japanese people who are accustomed to eating fish and shellfish and seaweed, the smell and flavor peculiar to seafood is not a big problem, but it is a big problem for Westerners who do not have such a practice. On the other hand, there were concerns about side effects when using a chemically synthesized drug that had the effect of suppressing an increase in blood glucose level.
- Non-patent literature 1 T. Nishiyama et al., Journal of Agricultural and Food Chemistry, 53, 2005) 959-963.
- Non-Patent Document 2 A. Hattori et al., J. Nutr. Sci. Vitaminol, 51 (2005) 382-384.
- Non-Patent Document 3 T. Miura et al., Biol. Pharm. Bull, 27 (2004) 248-250.
- Non-Patent Document 4 Morimoto et al., Yakugaku Zasshi, 122 (2002) 163-168.
- Non-Patent Document 6 Hosokawa, BIO INDUSTRY, 21 (2004) 52-57.
- Non-Patent Literature 7 1. Konisni et al., Omparative Biochemistry and Pnysiology. Part, P harmacology, toxicology & endocrinology, 142 (2006) 53-59.
- Patent Document 1 No. 2002-022140
- Patent Document 2 JP-A-2004-008165
- Patent Document 3 Japanese Patent Application Laid-Open No. 2004-329047
- Patent Document 4 Japanese Patent Laid-Open No. 2003-304830
- Patent Document 5 Japanese Patent Laid-Open No. 2002-212201
- Patent Document 6 Japanese Patent Laid-Open No. 2001-226275
- the present invention has been made in view of the problems of the prior art, and is a highly effective natural substance derived from many chemical substances derived from natural products that suppress the increase in blood sugar level. It is an object of the present invention to provide an agent for suppressing an increase in blood glucose level, which has no problem of odor and flavor and has no side effects.
- fucoxanthin is a typical phenomenon at the onset of diabetes, and increased the amount of drinking water, depending on the amount of fucoxanthin added. And found that it reduces blood sugar levels. That is, a substance having a large effect was identified from among many chemical substances derived from natural products that suppress the increase in blood glucose level. Therefore, by using fucoxanthin as an active ingredient, it was possible to effectively suppress an increase in blood glucose level. In addition, fucoxanthin has no odor or flavor peculiar to seaweed, so even if it is added to all foods and beverages, these odors and flavor are not impaired. This fucoxanthin is an ingredient contained in seaweeds such as seaweed, and since it has been eaten by Japanese people since ancient times, it can be safely used.
- the blood glucose level elevation inhibitor of the present invention is characterized by containing fucoxanthin as an active ingredient.
- the blood glucose level elevation inhibitor of the present invention is characterized in that fucoxanthin is added to any of foods, beverages, sublimates, pet foods, cosmetics, sanitary products, and drugs. .
- the fucoxanthin may be in a powder state, in a solid state, dissolved in an organic solvent, or emulsified using a surfactant.
- the fucoxanthin is one or two or more kinds selected from components extracted from natural products and purified, components obtained by organic synthesis, and components synthesized through microorganisms. What was obtained by the combination may be used.
- an increase in blood glucose level can be suppressed by using fucoxanthin as an active ingredient.
- fucoxanthin has no odor or flavor peculiar to seaweed, so even when fucoxanthin is added to foods, beverages, supplements, etc., it does not notice the difference in smell and taste from those without additives. It is possible to ingest and there is no problem of smell or flavor.
- Fucoxanthin is a component contained in seaweed that has been eaten since ancient times, and it can be used in a healthy and safe manner, with no side effects. Therefore, it is possible to suppress an increase in blood glucose level by including fucoxanthin as an active ingredient in foods, beverages, supplements, pet food, sanitary products, cosmetics and pharmaceuticals.
- fucoxanthin for example, extracted from dried wakame powder and isolated and purified using column chromatography can be used.
- Fucoxanthin added in this way is not limited to those extracted from seaweed force, but extracted from natural products including marine products and purified, obtained by organic synthesis, synthesized through microorganisms It can be a thing. Or they may be a combination thereof.
- fucoxanthin can be efficiently dissolved in an organic solvent such as ethanol to be added to foods, beverages, supplements, pet foods, sanitary products, cosmetics, and pharmaceuticals, and a surfactant can be used. It is also possible to emulsify using an agent (emulsifier). In other words, the form of fucoxanthin to be added, that is, the chemical 'physical state' is any state. It doesn't matter.
- fucoxanthin can be expected to have an anti-obesity effect including a fat accumulation effect (Non-patent Document 5) and a blood lipid reduction effect as effects other than the suppression of the increase in blood glucose level.
- a fat accumulation effect Non-patent Document 5
- a blood lipid reduction effect as effects other than the suppression of the increase in blood glucose level.
- Embodiment S The present invention is not limited to this embodiment.
- mice Three-week-old female KK-Ay mice were purchased from CLEA Japan as model mice for the onset of diabetes, and experimental breeding was performed after one week of preliminary breeding. Mice were housed under conditions of a temperature of 23 ⁇ 1 ° C, a humidity of 55 people, 10%, and lighted from 7 am to 7 pm (others were unlit). The time represents Japan time unless otherwise noted. During breeding, food and water were freely consumed. The feed was based on the AIN-93G composition (one of the standard compositions for breeding experiments that has been published by the National Institute of Nutrition).
- AIN-93G contains 13.5% by weight of soybean oil.
- soybean oil 13.5 wt% control mice administered AIN- 93 itself containing group, 0.1 wt% of soybean oil 13.5 wt 0/0, replacing the 2% by weight 0.1 to fucoxanthin
- the mice to which these were administered were designated as 0.1% fucoxanthin administration group and 0.2% fucoxanthin administration group, respectively.
- the fucoxanthin used here was extracted from dried wakame powder and isolated and purified using column chromatography.
- the amount of soybean oil in the feed replaced with fucoxanthin was 0. 0 by weight.
- the weight ratio may be increased or decreased.
- the 0.1% fucoxanthin administration group, and the 0.2% fucoxanthin administration group, 7 to 8 animals in each group were kept on the experimental diet for 25 days after one week of preliminary breeding.
- Start experimental breeding The total water consumption was measured for 3-9 days, 11 17 days, 19-25 days, and the daily water intake was measured during 19-25 days.
- Blood glucose was collected from the tail vein at 10:12 am under fasting on the 25th day after the start of experimental breeding, and measured using a commercially available blood glucose tester.
- the fucoxanthin-added food was ingested continuously for 25 days, but the ingestion period is not particularly limited to this example and may be intermittently performed.
- Fig. 1 shows the amount of water consumed per week in KK Ay mice given experimental samples
- Fig. 2 shows the amount of water consumed per day in week 4 of KK-Ay mice.
- the vertical axis is the amount of drinking water (mL).
- the amount of drinking water increases with the onset of diabetes.
- Non-Patent Document 4 “In diabetes, the osmotic pressure in tubules increases due to urine sugar, so water reabsorption is suppressed and urine volume increases, resulting in a decrease in tissue water content. It is explained that severe roaring occurs and the amount of drinking water increases.
- the fucoxanthin administration group when comparing the amount of water consumed between the control feed group, the 0.1% fucoxanthin administration group, and the 0.2% fucoxanthin administration group, the fucoxanthin administration group was either weekly or daily. A decrease in water consumption was observed. From these results, it was found that the intake of fucoxanthin-added feed can suppress the increase in water consumption, which is a physiological phenomenon at the onset of diabetes.
- FIG. 3 shows the blood glucose levels of KK-Ay mice 4 weeks after feeding the experimental diet.
- the vertical axis is blood glucose level (mgZmL).
- Fig. 3 in the group fed with fucoxanthin-added feed, a phenomenon of blood glucose level decrease depending on the fucoxanthin concentration was observed. The results of this direct decrease in blood glucose have been reported in the past!
- fucoxanthin has an action of suppressing an increase in blood glucose level.
- the test food was prepared according to the AIN-93G composition.
- Mice were pre-bred for 10 weeks on a high-fat diet (mixed fats such as lard and soybean oil: 30%) to make them obese. After pre-breeding, high fat diet group (mixed fat: 30%), fucoxanthin added group-1 (mixed fat (30%) + fucoxanthin (0.1%), fucoxanthin added group-2 (mixed fat (30%) + Fucoxanthin (0.2%) was raised for 4 weeks.
- high fat diet group mixed fat: 30%
- fucoxanthin added group-1 mixed fat (30%) + fucoxanthin (0.1%)
- fucoxanthin added group-2 mixed fat (30%) + Fucoxanthin (0.2%) was raised for 4 weeks.
- the temperature of the breeding room was 23 ⁇ 1 ° C, the humidity was 50%, and the brightness was 12-hour cycle. Feed and water were freely consumed.
- Fig. 4 shows a comparison of the blood glucose measurement results in the high fat diet group fed with only the high fat diet, the fucoxanthin added group-1 and the fucoxanthin added group-2.
- FIG. 5 shows the expression level of glucose transporter 4 (GLUT4) in the muscles of the high-fat diet group, the fucoxanthin-added group-1 and the fucoxanthin-added cocoon group-2 that were also fed with the high-fat diet. The results of the investigation are shown in comparison.
- GLUT4 was significantly increased by administration of fucoxanthin. This indicates that fucoxanthin has the effect of reducing blood glucose level due to the increase of GLUT4 in muscle and the accompanying uptake of sugar from blood into muscle and promotion of consumption.
- FIG. 6 shows a comparison of the results of measuring the gene expression level of GLUT4 in skeletal muscle cells (L6) with and without fucoxanthin added.
- the gene expression level of GLUT4 was significantly increased in skeletal muscle cells (L6) to which fucoxanthin was added compared to skeletal muscle cells (L6) to which no fucoxanthin was added. This indicates that fucoxanthin increases GLUT4 activity in the skeletal muscles, thereby promoting glucose uptake and consumption, thereby exhibiting antidiabetic activity.
- the present invention relates to a blood sugar level increase inhibitor comprising fucoxanthin as an active ingredient. Therefore, it can be used as a functional food material by adding fucoxanthin to food materials and the like in the medical field, and can be expected to be used in the agricultural field.
- FIG. 1 shows the amount of water consumed per week in KK-Ay mice fed with experimental feed in relation to Example 1, which is an example of the blood glucose level elevation inhibitor of the present invention, and the fucoxanthin administration group Is an explanatory diagram showing that there is a significant difference compared to the control group at any dosage level (P 0.01).
- FIG. 2 relates to Example 1, which is one example of the blood sugar level elevation inhibitor of the present invention, and shows the amount of water consumed per day on days 19-25 of KK Ay mouse, and any of the fucoxanthin administration groups
- FIG. 6 is an explanatory diagram showing that there is a significant difference in the administration level of (P ⁇ 0.01)) compared with the control group.
- FIG. 3 shows the blood glucose level of KK-Ay mice on the 25th day after feeding the experimental feed in relation to Example 1, which is an example of the blood sugar level elevation inhibitor of the present invention.
- the fucoxanthin administration group is!
- FIG. 3 is an explanatory diagram showing that there is a significant difference (P ⁇ 0.01) in comparison with the control group even in the dose level of deviation.
- FIG. 4 relates to Example 2, which is an example of the blood sugar level elevation inhibitor of the present invention, and shows a comparison of the blood glucose level measurement results in the high fat diet group and the fucoxanthin addition group.
- Glucose transporter 4 in muscle of high fat diet group and fucoxanthin addition group is an explanatory diagram showing the results of examining the gene expression level in comparison with each other and showing that a significant difference is observed in the fucoxanthin-added group compared to the high-fat diet-administered group (P ⁇ 0.01). )
- FIG. 6 shows a comparison of the results of measuring the gene expression level of GLUT4 in skeletal muscle cells (L6) to which fucoxanthin was added and skeletal muscle cells (L6) to which fucoxanthin was not added.
- FIG. 2 is an explanatory diagram showing that a significant difference is observed in skeletal muscle cells (L6) to which fucoxanthin is added compared to skeletal muscle cells (L6) (P 0.05)).
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008509896A JPWO2007116980A1 (ja) | 2006-04-07 | 2007-04-06 | 血糖値上昇抑制剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-105849 | 2006-04-07 | ||
JP2006105849 | 2006-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007116980A1 true WO2007116980A1 (ja) | 2007-10-18 |
Family
ID=38581259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/057790 WO2007116980A1 (ja) | 2006-04-07 | 2007-04-06 | 血糖値上昇抑制剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2007116980A1 (ja) |
WO (1) | WO2007116980A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008001623A (ja) * | 2006-06-21 | 2008-01-10 | Kyoto Univ | 血管新生抑制剤 |
WO2009048249A2 (en) * | 2007-10-10 | 2009-04-16 | Amicogen, Inc. | Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same |
WO2017018542A1 (ja) * | 2015-07-30 | 2017-02-02 | 北海道公立大学法人札幌医科大学 | フコキサンチンを含有する抗糖化組成物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995000130A1 (en) * | 1993-06-28 | 1995-01-05 | The Howard Foundation | Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism |
-
2007
- 2007-04-06 JP JP2008509896A patent/JPWO2007116980A1/ja active Pending
- 2007-04-06 WO PCT/JP2007/057790 patent/WO2007116980A1/ja active Search and Examination
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995000130A1 (en) * | 1993-06-28 | 1995-01-05 | The Howard Foundation | Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism |
Non-Patent Citations (7)
Title |
---|
HOSOKAWA M.: "Gan Saibo o Jimetsu saseru Kaiso Carotenoid-Fucoxanthin ni yoru Apoptosis Yudo", BIO INDUSTRY, vol. 21, no. 1, 2004, pages 52 - 57, XP003018163 * |
KUDO M.: "Kakunai Juyotai (PPARgamma) no Hatsugen Seigyo Sayo o Yusuru Shiyosei Kasseika Busshitsu no Kensaku", JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, no. 2-4IA04, 2002, pages 46, XP003018166 * |
MAEDA H. ET AL.: "Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 332, 2005, pages 392 - 397, XP004902490 * |
MAEDA H.: "Fucoxanthin no Seitainai Henkan to Shibo Saibo no Bunka Yokusei Koka", JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, no. 3J11P18, 5 March 2006 (2006-03-05), pages 206, XP003018164 * |
MAEDA H.: "Fucoxanthin to Chusa Shibosan oyobi Tocopherol Heiyo ni yoru Taishibo Gensho Koka", THE JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE, no. 3H-13P, 2006, pages 353, XP003018162 * |
MAEDA H.: "Fucoxanthin to Gyoku ni yoru Naizo Shibo no Chikuseki oyobi Koketto ni Taisuru Yokusei Koka", JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, no. 2B07A05, 2007, pages 133, XP003018167 * |
UCHIYAMA S. ET AL.: "Oral Administration of Beta-Cyptoxanthin Prevents Bone Loss in Streptozotocin-Diabetic Rats in Vivo", BIOL. PHARM. BULL, vol. 28, no. 9, 2005, pages 1766 - 1769, XP003018165 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008001623A (ja) * | 2006-06-21 | 2008-01-10 | Kyoto Univ | 血管新生抑制剤 |
WO2009048249A2 (en) * | 2007-10-10 | 2009-04-16 | Amicogen, Inc. | Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same |
WO2009048249A3 (en) * | 2007-10-10 | 2009-06-04 | Amicogen Inc | Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same |
WO2017018542A1 (ja) * | 2015-07-30 | 2017-02-02 | 北海道公立大学法人札幌医科大学 | フコキサンチンを含有する抗糖化組成物 |
JPWO2017018542A1 (ja) * | 2015-07-30 | 2018-06-07 | 北海道公立大学法人 札幌医科大学 | フコキサンチンを含有する抗糖化組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007116980A1 (ja) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5878954B2 (ja) | マルチプル・リスク・ファクター症候群を予防又は改善するための組成物 | |
JP5778912B2 (ja) | Igf−1分泌促進剤 | |
WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
TW201347681A (zh) | 含有咪唑胜肽與槲黃素配糖體之組成物 | |
JP6241000B2 (ja) | 耐糖能異常改善剤 | |
JP2005213227A (ja) | D−プシコースの血糖上昇抑制効果の利用 | |
KR101695848B1 (ko) | 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물 | |
JP2011157343A (ja) | 抗老化経口剤 | |
WO2012137953A1 (ja) | 動物用栄養組成物 | |
JP6445686B2 (ja) | ジペノサイド75の抗糖尿病効果 | |
JP5099812B2 (ja) | 血糖値上昇抑制剤 | |
JP2011207776A (ja) | アディポネクチン産生促進剤 | |
KR20120101286A (ko) | 당 대사 개선제 및 당 대사 개선 조성물 | |
TWI603732B (zh) | Contains sesamin-class and γ-furfuryl alcohol and rice germ oil composition | |
WO2007116980A1 (ja) | 血糖値上昇抑制剤 | |
WO2015193962A1 (ja) | 耐糖能異常改善剤 | |
JP2008231057A (ja) | 中性脂肪吸収調節組成物 | |
JP5156330B2 (ja) | 脂肪組織重量減少剤 | |
JP3433917B2 (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
JP2007230987A (ja) | 抗肥満剤 | |
JP2007031302A (ja) | アディポネクチン産生促進剤、及び代謝異常症候群予防剤 | |
JP6194192B2 (ja) | アディポネクチン産生促進剤 | |
TWI294284B (ja) | ||
TW200812569A (en) | Bone density increasing agent | |
JP5118316B2 (ja) | 肥満予防・改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07741226 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008509896 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07741226 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07741226 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |